14 completed, 4 recruiting, 1 active not recruiting, 1 unknown. 20 Phase 1.
By phase and status
Follow Phase 1: new trials by email Literature Review of Phase 1 trials Research Report on Phase 1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma NK Cells - Phase 1, NK Cell Phase 1 Recruiting 36 2026-08-21 2026-08-25 Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer SAR445877, FOLFOX6, Bevacizumab - Phase 1, SAR445877 Phase 1 Recruiting 41 2026-05-20 2026-11-02 A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants TNX-102 SL Tablet - Pharmakokinetic, Open Label Phase 1 Active not recruiting 50 2025-12-09 2026-02-17 Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma Lymphodepleting chemotherapy, Dexamethasone, Fludarabine - Clear Cell Carcinoma, Phase 1 Phase 1 Recruiting 30 2025-09-25 2026-04-29 Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel) Cyclophosphamide, Fludarabine - Phase 1, Recurrent Melanoma Phase 1 Recruiting 39 2025-02-25 2026-10-05 The Safety, Tolerability, Pharmacokinetics and Food Effects of SHEN211 Tablet in Healthy Subjects SHEN211 tablets, SHEN211 placebo tablets - Phase 1 Phase 1 Unknown 76 2023-12-14 2024-01-22 Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Dose of GV101 in Healthy Subjects GV101, Placebo - Phase 1 Phase 1 Completed 16 2021-09-10 2023-10-17 Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects Setanaxib - Phase 1 Phase 1 Completed 64 2020-06-24 2022-06-30 A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies NOV1601(CHC2014) - Phase 1, Solid Tumor, Adult Phase 1 Completed 17 2019-08-09 2021-09-16 PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI) Adalimumab - Phase 1 Phase 1 Completed 207 2019-07-01 2022-05-04 Safety Study of Dengushield in Healthy Adults Dengushield 1 mg/kg (Cohort 1) intravenous, Dengushield 3 mg/kg (Cohort 2) intravenous, Placebo 3 mg/kg (Cohort 2) intravenous - Phase 1, Dengue Phase 1 Completed 40 2019-03-22 2020-02-18 Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets GKT137831 - Phase 1 Phase 1 Completed 15 2018-12-19 2022-06-30 A Study to Examine the Effect of Tesofensine and Metoprolol on the 24-hour Mean Heart Rate Metoprolol Succinate 25 MG, Metoprolol Succinate 50 MG, Metoprolol Succinate 100 MG - Phase 1 Phase 1 Completed 37 2018-07-11 2024-02-09 A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy Volunteers PF-04965842, Midazolam - Phase 1 Phase 1 Completed 25 2018-07-03 2020-03-23 Pharmacokinetic, Safety and Tolerability Study of Altebrel in Healthy Male Subjects Etanercept - Phase 1, Bioequivalence Phase 1 Completed 34 2016-12-04 2018-09-19 A Study Of CinnoRA (Adalimumab-CinnaGen) And Adalimumab (Humira) In Healthy Subjects Adalimumab - Bioequivalence, Phase 1 Phase 1 Completed 74 2016-10-22 2018-09-19 A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels solifenacin succinate, mirabegron, mirabegron/solifenacin succinate - Phase 1, Bioavailability Phase 1 Completed 72 2012-09-01 2013-12-13 A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372. PF-05212372, Placebo - Phase 1, Single Dose Phase 1 Completed 24 2010-09-01 2011-08-15 A Study In Healthy People Of Multiple Doses Of UK-396,082 Given By Mouth, To Investigate The Safety, Toleration And Time Course Of Blood Concentration Of UK-396,082 And Its Effects. UK-396,082, placebo - Phase 1, Multiple Dose Phase 1 Completed 48 2010-03-01 2018-12-04 EC905 Pharmacokinetic Profile Study Tamsulosin HCl, Solifenacin Succinate, EC905 - Phase 1, Healthy Phase 1 Completed 46 2009-03-01 2015-12-18
Narrower conditions Adenocarcinoma, Clear Cell (1) · Colorectal Neoplasms (1) · Dengue (1) · Glioblastoma (1) · Lower Urinary Tract Symptoms (1) · Melanoma (1) · Prostatic Hyperplasia (1) · Urinary Bladder Neck Obstruction (1) · Urinary Bladder, Overactive (1) · Urinary Incontinence (1)
Broader conditions Neoplasms (4) · Neoplasms by Histologic Type (3) · Neoplasms by Site (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Glandular and Epithelial (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Adenocarcinoma (1) · Arbovirus Infections (1) · Astrocytoma (1) · Carcinoma (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Female Urogenital Diseases (1)
Interventions Adalimumab (2) · Solifenacin Succinate (2) · fludarabine (2) · setanaxib (2) · 5-amino-2-((1-n-propyl-1H-imidazol-4-yl)methyl)pentanoic acid (1) · Bevacizumab (1) · Cyclophosphamide (1) · Dexamethasone (1) · Etanercept (1) · Folfox protocol (1) · Metoprolol (1) · Midazolam (1) · Tamsulosin (1) · abrocitinib (1) · mirabegron (1)
Sponsors M.D. Anderson Cancer Center (4) · Pfizer (3) · Astellas Pharma Europe B.V. (2) · Calliditas Therapeutics AB (2) · Alvotech Swiss AG (1) · AryoGen Pharmed Co. (1) · Cinnagen (1) · Graviton Bioscience Corporation (1) · Handok Inc. (1) · JKT Biopharma Co., Ltd. (1) · Saniona (1) · Serum Institute of India Pvt. Ltd. (1) · Tonix Pharmaceuticals, Inc. (1)
Countries United States (5) · Belgium (3) · France (2) · Germany (2) · Iran (2) · Australia (1) · Canada (1) · China (1) · Netherlands (1) · New Zealand (1) · South Korea (1)
Top investigators Andrew C Johns, MD (1) · Aung Naing, MD (1) · Chibawany Ene, MD (1) · Dan Rudin, MD (1) · Dong-Wan Kim, MD, PhD (1) · Isabella C Glitza Oliva, MD (1) · Kim Krogsgaard, MD, DMSc (1) · Prasad Kulkarni, MD (1) · Sang-Joon Shin, MD, PhD (1) · Somayeh Amini, PharmD (1) · Tak Yun, MD, PhD (1) · Yong-Wha Moon, MD, PhD (1)
Results publications PMID 31985294 , PMID 33515429 , PMID 38408457 , PMID 38554232
NIH funding 2018 (1)